Selling, General, and Administrative Costs: Exelixis, Inc. vs Grifols, S.A.

SG&A Expenses: Exelixis vs Grifols - A Decade of Growth

__timestamp	Exelixis, Inc.	Grifols, S.A.
Wednesday, January 1, 2014	50829000	660772000
Thursday, January 1, 2015	57305000	736435000
Friday, January 1, 2016	116145000	775266000
Sunday, January 1, 2017	159362000	860348000
Monday, January 1, 2018	206366000	814775000
Tuesday, January 1, 2019	228244000	942821000
Wednesday, January 1, 2020	293355000	985616000
Friday, January 1, 2021	401715000	1061508000
Saturday, January 1, 2022	459856000	1190423000
Sunday, January 1, 2023	542705000	1254234000

Igniting the spark of knowledge

A Comparative Analysis of SG&A Expenses: Exelixis, Inc. vs Grifols, S.A.

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Exelixis, Inc. and Grifols, S.A. over the past decade, from 2014 to 2023.

Exelixis, Inc. has seen a remarkable increase in its SG&A expenses, growing by over 900% from 2014 to 2023. This surge reflects the company's aggressive expansion and investment in administrative capabilities. In contrast, Grifols, S.A. has maintained a more stable growth trajectory, with a 90% increase in the same period, indicating a steady scaling of operations.

This financial insight not only highlights the strategic priorities of these companies but also provides a window into their operational efficiencies and market positioning strategies.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025